opicapone
Sign in to saveOpicapone, sold under the brand name Ongentys, is a medication which is administered together with levodopa in people with Parkinson's disease. Opicapone is a catechol-O-methyltransferase (COMT) inhibitor.
Key facts
- Drug.UNII
- Y5929UIJ5N
- Drug.image
- Opicapone.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Ongentys, Ontilyv
- Drug.DailyMedID
- Opicapone
- Drug.pregnancy_AU
- B2
- Drug.pregnancy_category
- Not recommended
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- N04
- Drug.ATC_suffix
- BX04
- Drug.legal_AU
- S4
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.legal_status
- Rx-only
- Drug.bioavailability
- ~20%
- Drug.protein_bound
- 99.9%
- Drug.metabolism
- Mainly sulfation, also reduction, glucuronidation, methylation
via Wikipedia infobox
Article
13 sectionsContents
- Medical uses
- Contraindications
- Side effects
- Overdose
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- History
- Society and culture
- Legal status
- References
- Further reading
Opicapone, sold under the brand name Ongentys, is a medication which is administered together with levodopa in people with Parkinson's disease. Opicapone is a catechol-O-methyltransferase (COMT) inhibitor.
The most common side effects are dyskinesia (difficulty controlling movement), constipation, increased blood creatine kinase, hypotension/syncope, and decreased weight.